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Increasing the Clinical Efficacy of Radiotherapeutics for Solid Tumors by Inhibition of 
Hypoxia Inducible Factor-1a 
 
Abstract: Radiotherapy is commonly used in a variety of tumor types and is effective in control of long term 
progression and may be curative under certain circumstances. Radiotherapeutics have been shown to be the single 
most effective therapeutic for cancer and only account for 5% of the total cost. However, treatment of cells with 
radiation causes the tumor microenvironment to undergo changes and leads to cycles of hypoxia inside the tumor 
which allows for the cell to undergo angiogenesis, metastasize and may lead to repopulation of the tumor. Current 
systemic chemotherapeutics typically have an additive toxicity due to the unintended targeting of non-cancerous 
cells. A nanoparticle conjugated with the iRGD peptide is proposed to allow for selective uptake by the CendR 
pathway in the tumor tissues. A systemic selective chemotherapeutic agent that will inhibit hypoxia inducible factor-
1, preventing angiogenesis, that is co-administered with radiotherapy may increase the clinical efficacy of the 
radiotherapeutics and may have the greatest impact on currently available cancer treatment.
 Introduction 
 
            Radiotherapy (RT) is used as a 
treatment option for approximately 50% of all 
cancer patients. RT has shown to be effective 
in the control of the long-term progression of 
tumors and in a substantial proportion of cases 
can be curative (1). According to the National 
Cancer Institute, there are two main forms of 
radiotherapy, internal radiation therapy and 
external beam radiation. Internal radiation 
therapy requires the source of radiation to be 
put within one’s body. The form of radiation 
can either be solid or liquid. Internal radiation 
therapy with a solid source is termed 
brachytherapy and is a form of local 
treatment, meaning it treats only a specific 
part of your body. Internal radiation with a 
liquid source is called systemic therapy. This 
form of radiation will be transported in the 
blood to tissues throughout the body, where it 
will target and kill cancer cells. External beam 
radiation therapy is a form of local treatment 
that is accomplished by focusing a beam of 
radiation on the tumor (2).   
 
        Radiotherapy has been shown to activate 
a connected series of processes in tumor 
microenvironments including: inflammation, 
cycling hypoxia, revascularization and 
extracellular matrix remodeling (ECM) (3). 
Radiotherapy can cause cell death by inducing 
DNA damage. The induction of DNA damage 
is caused directly or indirectly by free radicals 
which are generated from the radiolysis of 
water.  In the presence of oxygen, O2, 
generation of reactive oxygen species occurs 
and acts as a positive feedback loop, further 
enhancing DNA damage (4).  
 
          Combining RT with a systemic 
treatment option, either with a biologically 
targeted chemotherapeutic or a cytotoxic 
chemotherapeutic to further enhance RT has 
had extensive interest in clinical research. A 
combinational therapy option would be 
beneficial over a prolonged course of RT due 
to the time it takes for DNA damage to cause 
cell death (5). One example of a current 
combination therapy option is the use of 
Cisplatin with RT which has shown to be 
beneficial for: head and neck, lung, 
esophageal, cervical, and bladder cancers (6). 
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This form of combinational therapy has 
shown to increase the clinical efficacy of RT, 
compared to if RT or cisplatin were used alone 
(7).  However, Cisplatin has the ability to 
arrest cells in the G2 phase of the cell cycle, 
and when it targets noncancerous tissues, it 
leads to an additive toxicity (7). 
           
 Due to this fact, research into systemic 
chemotherapeutics that will not lead to 
additive toxicity is necessary. In this 
literature review, the idea of using a 
nanoparticle that will induce inhibition of 
HIF-1a as a form of a biologically targeted 
systemic chemo-therapeutic agent along with 
RT to increase the clinical efficacy of RT is 
looked at as a possible new therapeutic 
approach.  
 
The tumor microenvironment 
 
Solid tumors are not only composed 
of malignant cancerous cells but also include 
a collection of stromal cells that are related 
to: angiogenesis, inflammation, and growth 
of fibrous or connective tissue (8). This 
creates an atypical ECM that harbors cells 
including: fibroblasts, immune cells, red 
blood cells, epithelial cells, and endothelial 
cells. The cancerous cells take advantage of 
the densely packed ECM via mutations to 
create a harsher environment that supports 
tumor progression and treatment 
resistance.(9) This environment is thought to 
arise during the rapid proliferation of the 
cancerous cells. During this state of tumor 
development, the cells use vast amounts of 
nutrients and oxygen from normal 
vasculature which quickly leads to a hypoxic 
state, an oxygen deprived state, and a nutrient 
deprived state inside the solid tumor (10). 
 
 The hypoxic state leads to the 
activation of the hypoxic pathway through the 
activation of the hypoxia inducible factor 1 
(HIF-1). HIF-1 is a heterodimeric protein 
consisting of 2 subunits, HIF-1a and HIF-1b. 
Both subunits are composed of basic helix-
loop-helix proteins, and when combined act as 
a transcription activator for the subset of HIF-
1 targeted genes (10). HIF-1b is a member of 
the Aryl hydrocarbon nuclear translocator 
family, and is only found in the nucleus (11). 
Meanwhile, HIF-1a under normal oxygen 
conditions is found in the cytosol and 
undergoes rapid degradation (9).  
HIF-a degradation is associated with 
the enzyme proline hydroxylase. Under 
normal oxygen conditions, HIF-a is 
transcribed and translated at a high rate but 
almost immediately undergoes degradation. 
Proline hydroxylase is responsible for the 
oxidation of 1 or 2 proline residues of HIF-1a 
to hydroxyproline. After conversion to 
hydroxyproline, pVHL will bind to HIF-1a, 
and catalyze the addition of numerous 
ubiquitin molecules to the protein. Ubiquitin 
acts as a biological tag, and will signal for 
HIF-1a to be degraded in a proteasome (9).  
 
In oxygen deprived conditions, 
proline hydroxylase fails to oxidize the 
proline residues. This allows for HIF-1a to 
evade degradation, allowing for the protein to 
translocate to the nucleus where it binds with 
HIF-1b and forms the heterodimeric protein 
leading to its activation (1). In previous 
studies, it has been found there are three 
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variants to the HIF heterodimeric protein 
which contain variant a subunits. These 
variants are termed as HIF-1a, HIF-2a and 
HIF-3a (12). HIF-1a and 2a have been 
shown to act similarly except in rare 
occasions of overexpression of the a-
subunits in different cancer subtypes. HIF-3a 
has actually been shown to inhibit HIF-1a 
and HIF-2a (12). In this article, the focus is 
on the variant HIF-1a and how it leads to 
changes in the tumor microenvironment 
during hypoxic states inside solid tumors.  
 
Disarrayed vasculature  
 
Cytokine signaling for activation of 
endothelial cells during cycles of hypoxia 
inside solid tumors is known to cause 
formation of new vasculature by a process 
called angiogenesis (13). A hallmark 
regulator of angiogenesis is the hypoxic 
pathway. Upon formation of the 
heterodimeric transcription factor HIF-1, 
gene transcription for over 200 genes 
becomes induced. Of these 200 genes, which 
mostly are poorly understood, there are three 
main pro-angiogenic factor genes known to 
induce angiogenesis: Vascular endothelial 
growth factor (VEGF), platelet-derived 
growth factor (PDGF), and transforming 
growth factor-a (TGF-a) (9).  VEGF will 
induce the recruitment and maturation of 
endothelial cells to form new capillaries 
within the solid tumor (14). PDGF stimulates 
mesenchymal cells, such as fibroblasts and 
pericytes which are associated with 
endothelial cells and help in the formation of 
new capillaries. TGF-a stimulates the 
recruitment and maturation of many types of 
cells to the tumor ECM including epithelial 
cells (9).  
 
When forming new vasculature, first 
there must be some degradation of the 
existing ECM to create space for the 
formation of the new vessels. Matrix 
metalloproteinases (MMPs) are responsible 
for this degradation. MMP-2 is known to be 
directly expressed upon activation of HIF-1 
(11). In the ECM, after degradation occurs, 
newly recruited endothelial cells will migrate 
to the area and form new endothelial tubes. 
These endothelial tubes are the primary 
structure of new capillary beds. Branching of 
these tubes is known to arise during 
modulation of Notch signaling. HIF-1a is 
responsible for the modulation of the Notch 
signaling by directly binding to the Notch 
intracellular domain. Newly recruited 
endothelial cells will begin forming tubes 
that extend from existing vascular network 
on the leading edge. After formation of these 
newly formed tubes, the immature 
endothelial cells will recruit vascular 
supporting cells, which have already been 
recruited to the tumor microenvironment by 
PDGF. The supporting cells include pericytes 
and smooth muscle cells that will form the 
basement membrane around the endothelial 
tube, leading to the formation of new 
vasculature and capillary beds. The final step 
in the formation of the vasculature is 
accomplished by fibronectin. Expression of 
fibronectin has been shown to be directly 
regulated HIF-2a in hypoxic states (11).  
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New vasculature formation is 
disarrayed when compared to that of normal 
tissue. Upon modulation of Notch signaling, 
by HIF-1a, extensive branching occurs in the 
newly formed vasculature. In normal tissue, 
branching of the vasculature is under tight 
regulation. Every cell needs to be within a 
certain distance, approximately 40 microns 
between adjacent capillaries, to ensure 
adequate oxygen and nutrients are available 
for the cells. Typically, in most living tissue 
there is only 1 to 3 cells that span the width 
of a capillary bed(15).  
 
In solid tumors, it has been shown 
that this branching is more extensive, due to 
the rapid proliferation of the tumor cells. 
Rapid proliferation means the tumor will 
have a higher metabolic demand, which leads 
to the production of excessive pro-angiogenic 
factors. Also, tumor vessels are continuously 
being remodeled inside solid tumors, leading 
to endothelial cells losing contact with the 
basement membrane, causing the capillary 
beds to rupture. The rupturing of capillaries 
causes the vessels to have larger pores and 
become leaky (16).   
 
 Tumor hypoxia effects  
 
The network of vasculature that is 
formed during cycles of hypoxia inside 
tumors is known to cause an increase in 
interstitial fluid pressure (IFP) and solid 
tissue pressure (STP) due to the rupturing of 
capillaries and the lack of formation of 
lymphatic vessels inside solid tumors. In 
most solid tumor animal models, IFP will 
increase between 10-100 mmHg (17). Due to 
the leakage the capillary beds, excessive 
leakage of proteins and fluids occur. This 
leads to an elevated microvascular pressure 
(MVP) and a decreased osmotic pressure 
compared to that of normal tissue. The fluid 
buildup in the tumor is a result of the lack of 
lymphatic vessels that normally uptake 
excess fluid present in the interstitial fluid 
(1). Due to these changes, there are 
implications for the delivery and uptake of 
nanoparticles into solid tumors.  
 
 Along with the buildup of fluid, the 
cancerous cells are undergoing rapid 
proliferation which leads to an increase in 
STP. As STP increases, there is a direct 
correlation with the collapse of vasculature. 
This leads to an increase in vascular blood 
flow resistance, resulting in a greater increase 
of IFP and MVP promoting the accumulation 
of more fluid in the interstitium of the tumor 
(1). Depending on the location in the tumor, 
IFP changes due to STP. In the center of the 
tumor, there is the greatest density of cells, 
leading to a high STP. This leads to a 
uniform elevation of IFP that will approach 
MVP. When IFP is near or equal to that of 
MVP, there is a limited transport of 
pharmaceuticals, oxygen and nutrients (1).   
 
Near the edges of tumors, there is a 
decrease in STP because there is a lower 
density of cells. This means that there will be 
a lower IFP on the edges of tumors, but 
because it is higher than that of surrounding 
tissue, there is a possible outflow of fluid 
into surrounding tissue (1).  This 
representation of the solid tumor 
microenvironment explains how the 
insufficient fluid flow works in favor of the 
tumor, allowing it to evade the immune 
INCREASING THE EFFICACY OF RADIOTHERAPEUTICS 
 
7 
system by preventing antigen presenting cells 
from leaving the tumor and preventing the 
uptake of chemotherapeutics into the core of 
the tumor.  
 
Individuals with solid tumors that 
have cycles of hypoxia are known to have 
poor prognoses (18). This is due to the 
positive correlation in cycling hypoxia 
leading to increased tumor aggressiveness 
and resistance to radiotherapy and 
chemotherapeutics (18). As shown 
previously, cycling hypoxia within solid 
tumors leads to the formation of new 
vasculature, that presents implications for the 
uptake of chemotherapeutics and certain 
radiotherapeutics.  
 
According to the National Cancer 
Institute, tumor aggressiveness is defined by 
the ability of a tumor to form, grow, or 
spread quickly (19). For a tumor to spread, 
metastasize, the tumor cells will undergo an 
epithelial-to-mesenchymal transition (EMT). 
For an EMT to occur, there are a variety of 
transcription factors that need to be activated. 
Two of these transcription factors are 
TWIST1 and SNAIL1. 
 In a study conducted by Yang et al., 
it was shown that HIF-1a regulates the 
expression of TWIST1 upon binding to the 
hypoxia-response element (HRE) which is 
found in the proximal promoter of TWIST1 
(20). This means HIF-1a is directly 
correlated to the ability of the tumor to 
promote metastasis leading to a worse 
prognosis. However, when they used siRNA-
mediated repression of TWIST1 in an 
environment where HIF-1a was over 
expressed, the cells reversed the EMT and 
metastatic phenotypes (20). This implicates 
the direct correlation of HIF-1a and 
metastasis, showing that TWIST1 is 
responsible for the EMT.  
 
According to K.J. Wu, who created a 
method for predicting metastatic potential in 
head and neck squamous cell carcinomas 
(HNSCCs) that co-express: HIF-1a, 
TWIST1 and SNAIL1, there was more than a 
90% probability of metastasis. Comparing 
that to HNSCCs that co-express TWIST1 and 
SNAIL1, not HIF-1a,  only had a 50% 
probability of metastasis (21). Based on his 
predictions, HNSCCs that co-express all 
three proteins have a substantially greater 
probability of metastasis, leading to a poorer 
prognosis and patient survival rate.  
 
TWIST1 is unique because not only 
does it help trigger an EMT, but it also has 
been shown to facilitate tumor cells to escape 
the senescence program found within every 
eukaryotic cell (22). The senescence program 
determines how many times a cell is allowed 
to replicate before it become senescent, the 
inability to proliferate, acting as a 
generational clock. In a normal cell, this is 
typically around 70 cell cycles. Upon 
completion of each cell cycle, the telomeres 
at the end of the DNA will be shortened (9). 
This means tumor cells expressing TWIST1 
have the ability to replicate with telomere 
lengths that would normally trigger 
apoptosis.   
 
 When cells are allowed to replicate 
without a proper senescence program, there 
is an increase in genomic instability. This 
occurs due to chromosomal end-to-end 
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fusions that are called breakage-fusion-
bridge (BFB) cycles. Telomeres normally 
prevent this from occurring by capping the 
ends of chromosomes. When chromosomes 
become uncapped, such as in a cell without a 
proper senescence program, BFBs cause the 
fusion of sister chromatids and random 
breaks, which may cause new mutations to 
occur (23). The formation of new mutations 
in the DNA of the cancerous cells may 
increase tumor aggressiveness by inducing 
changes that increase the ability of the 
cancerous cell to proliferate, grow, or to 
metastasize.   
 
Effect of radiotherapy on the tumor 
microenvironment  
 
 Radiation therapy is known to kill 
cancer cells by directing high physical 
energy in forms of radiation onto the cancer 
cells. RT has been used as a cancer 
therapeutic since the late 19th century. 
Through years of research, numerous 
advancements have been made in the clinical 
efficacy of RT (2). As we gain a better 
understanding of the molecular mechanisms 
in treatment sensitivity and resistance, these 
advancements have been made possible. RT 
is most commonly used in the treatment of 
localized malignant tumors during the 
progression of cancer.  Recent studies have 
shown that radiotherapy is the single most 
cost-effective cancer therapeutic and 
accounts for only 5% of the total cost of 
cancer care. Due to this fact, increasing the 
clinical efficacy of RT would benefit the 
largest number of patients (5).  
 
Tumor cell death 
 
Radiotherapy directly causes tumor 
cell death, resulting in the reduction of the 
cell population by numerous mechanisms. 
Ionizing radiation can act on the cancer cells 
by causing direct damage to the cell 
membranes leading to cell lysis (5). Also, 
ionizing radiation can lead to the production 
of free radicals which are produced by the 
ionization or excitation of water within the 
cells. These free radicals can cause direct 
DNA damage, which will not cause direct 
cell death, but if not repaired, will lead to 
cancer cell death. The most lethal forms of 
DNA damage will induce double stranded 
breaks which will result in cell death if not 
repaired adequately. However, if the cancer 
cell is able to adequately repair the DNA 
damage, the cell will be able to survive and 
increase their genomic stability (5).  
 
 During the course of a multi-day 
course of RT to a radio-responsive tumor, the 
total mass of the tumor will be decreased, 
leading to a decrease in the tumor’s 
production of pro-angiogenic cytokines, 
which causes the endothelial cells making up 
the vasculature to destabilize, leading to the 
regression of the vasculature (1).  This will 
ultimately lead to the tumor to have a 
decrease in blood supply, lowering the 
availability of nutrients and oxygen and will 
trigger the portion of solid tumor that is still 
intact to become hypoxic. Activation of the 
hypoxic pathway has been well known to 
occur following radiation treatments.  
INCREASING THE EFFICACY OF RADIOTHERAPEUTICS 
 
9 
 
 
Effects of hypoxia pathway post-treatment 
 
Angiogenesis has been shown to be  
correlated with activation of the hypoxic 
pathway. Upon completion of treatment with 
RT, solid tumors have been shown to 
experience hypoxia. After RT, it has been 
shown that in solid tumors, the 
proangiogenic cytokines increase 
dramatically in the following 6-8 hours (18). 
This means, if the patient is undergoing RT 
every other day, by the beginning of the next 
round of RT, the tumor will have already 
undergone angiogenesis and may have 
possibly repopulated due to the resupply of 
nutrients and oxygen to the solid tumor.  
 
Cancer stem cells (CSCs) are the main 
reason for tumor regrow after the 
completion of a course of RT. 
CSCs are fully capable of repopulating a 
tumor due to their ability to activate 
telomerase, an enzyme that increases the 
length of telomeres, giving the cells the 
ability to replicate without a senescent 
program. The majority of the cells that make 
up the human body do not have this ability. 
Thus, if CSC’s arise, they play a key role in 
inhibiting an effective cancer treatment.  
Recent studies have provided evidence that 
suggests hypoxia promotes the persistence of 
stem cells (24). In a study by Gianluca 
D’Ippolito, mesenchymal cells were isolated 
and cultured at various levels of oxygen. It 
was found that under higher levels of 
oxygen, differentiation was more likely to 
occur. Also, when the PO2 was decreased, 
mimicking a hypoxic environment, the stem 
cells were more likely to not differentiate and 
maintained their self-renewal capabilities 
(25).  
 
 CSCs have also been directly 
correlated with a solid tumor’s ability to 
undergo metastasis, a process that was 
explained above to also be influenced by 
hypoxia. Stated by Richard Hill, “The 
potential role of hypoxia in enhancing EMT 
and stemness in cells raises the possibility 
that the adverse effects of tumor hypoxia 
might be partially explained by its dual 
effects of promoting EMT and the self- 
renewal of CSCs” (24). Treatment resistant, 
or commonly known as radio-resistant, cells 
provide an obstacle during the course of RT 
treatment. If radio-resistant cells are present 
in the tumor, the RT will be ineffective at 
clearing the totality of the tumor mass (1).  
 
Nanoparticle based radio-chemotherapy  
 
Nanotherapeutic specific for HIF-1a 
inhibition 
 
Currently, a surplus of HIF-1a 
inhibitors have been created and designed. 
However, these inhibitors have been shown 
to have numerous downstream effects, 
leading to the creation of adverse effects 
when used as a systemic chemotherapeutic 
agent (26). Lack of targeting HIF-1a on the 
surface of cancerous cells has been an 
important obstacle in the creation of a 
systemic chemotherapeutic agent. Also, HIF-
1 has numerous downstream affects due to its 
ability to upregulate numerous genes which 
increases its risk of additive toxicity (10). 
However, if we are able to specifically target 
the inhibition of HIF-1a only in cancer cells, 
there would be a decrease in adverse effects 
and would result in a systemic 
chemotherapeutic that would have an 
increased efficacy(3).  
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As described above, the vasculature in solid 
tumors is unlike that of normal tissue. The 
endothelial cells are more spaced out, 
creating larger pores, leading to the 
vasculature to be leakier. Due to this, it is 
proposed to design of a nanoparticle that 
would be larger than that of the pores of 
normal vasculature, which is in the range of 
6-12 nm (27).  
 
Delivery of nanotherapeutics to solid tumors 
is believed to be increased by administering 
the nanoparticle systemically. By creating a 
stable nanoparticle that has a long half-life, 
the chances of it actually reaching the 
vasculature and being transported into the 
solid tumor without crossing the normal 
vasculature wall will decrease adverse effects 
(27). Renal clearance of particles that are 
smaller than 6 nm is very rapid and clearance 
of particles in the spleen of a nanoparticle 
that is larger than 200nm will also increase 
(27). Based on these findings, a particle in 
the range of 12-200 nm would have an 
increase in half-life, thereby increasing the 
possibility that it would enter the solid tumor.  
 
Nanoparticles that are currently in 
clinical trials are typically found to have a 
size within this range (27). The most 
common type of nanoparticle that has been 
tested in these clinical trials uses a liposomal 
formulation, which can be designed to be a 
specific size(28). By using a liposomal 
formulation, the nanoparticle delivery is 
believed to increase, and can be designed so 
that upon uptake into the tumor 
microenvironment, based on physiological 
characteristics such as pH, targeted release of 
the HIF-1a inhibitor could be achieved (28).   
 
Specific targeting and the synergist effects of 
radio-chemotherapy  
 
 Specific targeting of solid tumors by 
a chemotherapeutic through the CendR 
pathway has been under extensive research. 
The CendR pathway involves a three-step 
process using a tumor targeting peptide 
(TTP) sequence leading to the formation of 
endocytic vesicles that are approximately 
200nm (29). In the first step, an integrin-
binding RGD (iRGD) sequence motif within 
the TTP binds to avb3 and avb5 integrins 
which are specifically expressed by tumor 
endothelial cells. Upon binding, the sequence 
is cleaved by an unknown protease leading to 
the activation of a second motif in the 
sequence, the CendR motif (R/KXXR/K). 
The CendR motif can then bind to 
neuropilin-1 and neuropilin-2, which 
activates the CendR endocytotic pathway 
(29).  
 The CendR pathway is most similar 
to macropinocytosis; however, unlike 
macropinocytosis, it is receptor dependent. 
The required receptor is the neuropilin 
receptor. Upon activation of the receptor, the 
endocytic vesicles will form, which can 
uptake any particle small enough into the cell 
such as a nanoparticle (30). The nanoparticle 
will then be released into the cytoplasm and 
is free to undergo its own specific activity. In 
this case, the activity would act as an 
inhibitor of HIF-a, which would prevent its 
translocation into the nucleus and prevent 
activation of the HIF transcription factor.  
  
Along with the upregulated 
expression of the avb3 and avb5 integrins in 
the tumor endothelial tissue, the neuropilin 
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receptor is also overexpressed, leading to an 
upregulated activation of the CendR pathway 
(29). The receptor is upregulated due to the 
fact that tumors are typically in a nutrient 
deprived state. The enzyme mTOR acts a 
senor for nutrients, and when it senses a 
deprived state, it will signal for the 
overexpression of neuropilin (29). Neuropilin 
has been shown to be overexpressed in a 
wide variety of tumors including: prostate, 
breast, melanoma, pancreas and glioblastoma 
cancers (28). One advantage to this specific 
receptor is that it has not been shown to be 
upregulated on endothelial cells in normal 
vasculature. Due to this fact, peptides that 
bind to the neuropilin receptors are termed 
TTPs (28). Also, it has been found that drugs 
that are conjugated with the iRGD peptide 
have an increased accumulation in tumors by 
4-5-fold. This was shown in mice models 
with solid tumors (31).  
 
 Currently evidence is strongest for 
the use of nanoparticles conjugated with the 
iRGD peptide. However, it is believed that 
liposomes may be able to be modified with 
the iRGD peptide allowing for the activation 
of this pathway. Liposomes are suitable for 
nano drug delivery due to their controllable 
size and their ability to be modified (28). The 
issue that arises with the use of liposomes is 
that they have been shown to not penetrate 
deep into tumors as well as nanoparticles due 
to the complexity of the highly dense ECM 
and the rapidly increasing IFP in the center 
and periphery of the tumor (28). Because of 
this fact, it is proposed at the time to further 
study the conjugate of a HIF-a inhibitor with 
the iRGD peptide, which will avoid the 
obstacles that are present with the use of 
liposomes.  
 
 Increased clinical efficacy of 
radiotherapy can possibly be achieved with a 
targeted release of an HIF-1a inhibitor (4). 
By using a systemic chemotherapeutic such 
as the one proposed in combination with 
normal RT treatment could prevent the 
adverse effects that are seen upon activation 
of the hypoxia pathway due to RT treatment. 
Using this approach would prevent the 
formation of new vasculature within the solid 
tumor and could possibly cause necrosis of 
the tumor due to lack of access to adequate 
nutrients and oxygen. With the hypoxia 
pathway already inhibited, the tumor would 
not be able to undergo angiogenesis and 
could possibly prevent future metastasis from 
occurring, which both have been shown to be 
upregulated by HIF-1 formation. 
 
Increased efficacy for cancer-type 
specific chemotherapeutics would be 
beneficial if there are CSCs present in the 
solid tumor. CSCs are responsible for the 
regrowth of new tumors and must be 
eliminated to prevent future relapses (24). 
Upon completion of a round of combined RT 
with a specific HIF-1a inhibitor, the solid 
tumor will have decreased blood flow, 
decreasing the chances of the 
chemotherapeutic from reaching the CSCs. 
However, if there are CSCs present that are 
radio-resistant, research has shown, the best 
treatment option typically relies on the use of 
present systemic chemotherapeutics (24). 
Since there will be a decrease in the overall 
mass of the solid tumor, the systemic 
chemotherapeutics could possibly have a 
better chance of targeting the CSCs, which 
would lead to the increased efficacy. This is 
outside the scope of this paper, but it may 
benefit from future research upon successful 
formulation of the combined RT, HIF-1a 
treatment plan.  
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Conclusion 
 
 Radiotherapeutics have been shown 
to be an effective treatment option for a 
variety of tumor types in controlling tumor 
progression and may being curative under 
certain circumstances. Although radiotherapy 
is effective, it has been shown to cause 
changes in the makeup of the tumor 
microenvironment leading to cycles of 
hypoxia. Although theses cycles have no 
initial impact on the tumor, they may lead to 
downstream effects such as angiogenesis, 
tumor proliferation and tumor metastasis, 
which are correlated with a worse prognosis. 
These effects have been shown to be 
correlated with the activation transcription 
factor HIF-1 during a hypoxic state. 
Activation of the transcription factor occurs 
when HIF-1a subunits translocate from the 
cytoplasm into the nucleus and bind with the 
HIF-1b subunits and leads to an increase in 
the expression of VEGF, PDGF, and TGF-a 
along with a variety of other genes.  
 
 When angiogenesis occurs in the 
tumor microenvironment, the vasculature is 
disarrayed compared to that of normal 
vasculature due to the overexpression of pro-
angiogenic factors. The vasculature is leakier 
leading to the accumulation of excessive 
fluid and proteins inside the tumor. Also, as 
the cells deep within the tumor are 
proliferating, STP increases due to the 
increase in cell density. Together, this leads 
to an increase in the IFP which has been 
shown to hinder the distribution of 
chemotherapeutics deep in the tumor.  
 
 Tumor targeting peptides, which 
express a iRGD motif, selective for 
endothelial cells within the tumor have 
shown promising in mice models to increase 
the accumulation of nanoparticles deep 
within tumors upon activation of the CendR 
pathway. A nanoparticle that can inhibit the 
translocation of HIF-a subunits into the 
nucleus that is conjugated with a iRGD motif 
may prevent the accumulation of excess pro-
angiogenic factors in the tumor 
microenvironment post-treatment by 
radiation. Therefore, this nanoparticle could 
potentially increase the clinical efficacy of 
radiotherapeutics and being selective to only 
tumor tissue would decrease the risk of 
additive toxicity.  
 
Limitations 
 
 HIF-1 has been highly correlated with 
the accumulation of pro-angiogenic factors; 
however, they are not the only transcription 
factors that can signal for their 
overexpression. Therefore, although HIF-1 
inhibition may successfully prevent 
angiogenesis, cell growth/proliferation and 
metastasis, there may be other pathways that 
the cell could activate to accommodate the 
revascularization of the tumor (9).  
 
Future Research 
 
 This is a proposal of a new 
conjugated nanoparticle that has yet to be 
made or tested in a laboratory or clinical 
setting. Thus, research needs to be completed 
in the creation and efficacy of the proposed 
selective chemotherapeutic and on how 
specifically it is taken up by the tumor, how 
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much it may decrease the accumulation of 
pro-angiogenic factors and if the cancerous 
cells will activate other pathways to 
revascularize the tumor. 
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Appendix A 
 
Formatting of this paper was completed following the National Library of Medicine (NLM) 
guidelines.  
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